- Home
- LENZ vs AVBP Comparison
LENZ vs AVBP Comparison
Compare LENZ & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LENZ
- AVBP
- Stock Information
- Founded
- LENZ 2019
- AVBP 2021
- Country
- LENZ United States
- AVBP United States
- Employees
- LENZ N/A
- AVBP N/A
- Industry
- LENZ Medicinal Chemicals and Botanical Products
- AVBP
- Sector
- LENZ Health Care
- AVBP
- Exchange
- LENZ Nasdaq
- AVBP NYSE
- Market Cap
- LENZ 729.6M
- AVBP 617.4M
- IPO Year
- LENZ 2021
- AVBP 2024
- Fundamental
- Price
- LENZ $23.82
- AVBP $18.14
- Analyst Decision
- LENZ Strong Buy
- AVBP Strong Buy
- Analyst Count
- LENZ 5
- AVBP 6
- Target Price
- LENZ $40.20
- AVBP $39.00
- AVG Volume (30 Days)
- LENZ 297.4K
- AVBP 271.0K
- Earning Date
- LENZ 03-19-2025
- AVBP 05-07-2025
- Dividend Yield
- LENZ N/A
- AVBP N/A
- EPS Growth
- LENZ N/A
- AVBP N/A
- EPS
- LENZ N/A
- AVBP N/A
- Revenue
- LENZ N/A
- AVBP N/A
- Revenue This Year
- LENZ N/A
- AVBP $63.13
- Revenue Next Year
- LENZ $539.55
- AVBP N/A
- P/E Ratio
- LENZ N/A
- AVBP N/A
- Revenue Growth
- LENZ N/A
- AVBP N/A
- 52 Week Low
- LENZ $14.42
- AVBP $14.35
- 52 Week High
- LENZ $38.93
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- LENZ 52.20
- AVBP 43.66
- Support Level
- LENZ $21.91
- AVBP $15.55
- Resistance Level
- LENZ $24.39
- AVBP $18.72
- Average True Range (ATR)
- LENZ 2.26
- AVBP 1.19
- MACD
- LENZ 0.15
- AVBP 0.34
- Stochastic Oscillator
- LENZ 67.67
- AVBP 76.95
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.